Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Annovis Bio, Inc. (ANVS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANNOVIS BIO, INC."
05/30/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
04/04/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
04/03/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "ANNOVIS BIO, INC. Common Stock ATM EQUITY OFFERING SM SALES AGREEMENT",
"MEXICO CITY"
04/03/2023 8-K Quarterly results
Docs: "Publication of Phase 1/2 clinical data in The Journal of Prevention of Alzheimer's Disease"
03/31/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
02/13/2023 8-K Quarterly results
01/06/2023 8-K Investor presentation
Docs: "Presentation"
09/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and General Release, by and between the Company and Jeffrey B. McGroarty"
08/30/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re:",
"Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer"
08/08/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
11/15/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Annovis Bio Announces Transfer of Listing to the New York Stock Exchange"
11/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Annovis Bio Presented at the 14 th Clinical Trials on Alzheimer’ s Disease Conference"
10/05/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’ s Disease",
"Presentation – New Parkinson’s Efficacy Data, (furnished herewith)"
08/11/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Frequently Asked Questions Annovis Bio Phase 2a Data Results 1. What interim results from the Phase 2a study of ANVS401 were recently announced by Annovis Bio? Why did some people believe the company’ s recent interim data readout was negative? Answer: On July 28, we announced interim results among both Alzheimer’ s disease and Parkinson’ s disease patients from Phase 2a clinical trials of our lead compound, ANVS401 . The results were positive – over the first 25 days of treatment, the initial patient cohorts demonstrated statistically significant positive results in both cognitive and motor skills. The biomarkers presented and analyzed also corroborated the efficacy of ANVS401. We are aware that some initial reporting after our presentation at the AAIC 2021 conference included an error in..."
07/28/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
06/09/2020 8-K Investor presentation
Docs: "Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit BERWYN, PA. – June 9, 2020 – Annovis Bio Inc. , a clinical-stage drug platform company addressing Alzheimer’ s disease , Parkinson’ s disease and other neurodegenerative diseases, today announced that CEO Maria Maccecchini, Ph.D. and CFO Jeff McGroarty, MBA, CPA, will give a virtual corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9 to 12, 2020. Annovis Bio’ s presentation will be held on Wednesday, June 10, 2020 at 10:55 a.m. ET, followed by a live Q&A session. Investors can register for and access the live webcast at: https://www.webcaster4.com/Webcast/Page/2038/35035. Dr. Maccecchini and Mr. McGroarty will also be available for one-on-one meetings online. To registe...",
"Investor Presentation"
06/05/2020 8-K Submission of Matters to a Vote of Security Holders
04/03/2020 8-K Other Events
02/06/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of Annovis Bio, Inc",
"Amended and Restated By-laws of Annovis Bio, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy